Consolidation cetuximab after concurrent triplet radiochemotherapy + cetuximab in patients with advanced head and neck cancer: A randomized phase II study.

CONCLUSIONS: There was no evidence that consolidation cetuximab would improve the 2-year LRC rate. Prognostic biological and imaging markers could be identified for the overall patient cohort. Studies with larger patient numbers are needed to correlate biological and imaging markers. PMID: 32540337 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32540337?dopt=Abstract

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - June 11, 2020 Category: Radiology Authors: Riesterer O, Pruschy M, Bender S, Sharma A, Bogowicz M, Tanadini-Lang S, Stieb S, Bertogg K, Weber S, Ikenberg K, Huber G, Schmid S, Bredell M, Veit-Haibach P, Rordorf T, Held U, Glanzmann C, Studer G Tags: Radiother Oncol Source Type: research